Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1986 May;45(5):396-9.
doi: 10.1136/ard.45.5.396.

Sulphasalazine in ankylosing spondylitis

N Feltelius, R Hällgren
Clinical Trial

Sulphasalazine in ankylosing spondylitis

N Feltelius et al. Ann Rheum Dis. 1986 May.

Abstract

In recent years sulphasalazine has gained acceptance as an effective agent for the treatment of rheumatoid arthritis. Ankylosing spondylitis is a disease where remission inducing drugs so far have been lacking. In this double blind trial sulphasalazine was compared with placebo in 37 patients with ankylosing spondylitis. Evaluation after three months' treatment showed reduction of inflammatory activity and improvement of clinical variables. The side effects were mild. The results suggest that sulphasalazine is a potentially effective and safe drug in the treatment of ankylosing spondylitis.

PubMed Disclaimer

References

    1. Clin Exp Immunol. 1978 Aug;33(2):217-24 - PubMed
    1. Scand J Gastroenterol. 1978;13(8):991-7 - PubMed
    1. Br Med J. 1980 Feb 16;280(6212):442-4 - PubMed
    1. Br J Pharmacol. 1980 Apr;68(4):719-30 - PubMed
    1. Br Med J. 1962 Dec 29;2(5321):1708-11 - PubMed

Publication types